MetaCap

Accuray (ARAY) vs Baird Medical Investment (BDMD)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Accuray (ARAY) has outperformed Baird Medical Investment (BDMD) over the past year, gaining 97.6% versus a loss of 93.6%. Accuray is the larger company by market cap ($6.2 million vs $5.1 million), about 1.2 times the size. Accuray converts more of its revenue into profit, with a net margin of -12.2% versus -121.0%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ARAY+97.62%BDMD-93.64%
+282%+85%-112%
Nov 21, 20251 yearNov 20, 2026
ARAY-57.04%BDMD-99.08%
+24%-41%-105%
Dec 13, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ARAY versus BDMD key metrics
MetricARAYBDMD
Share price$2.08$0.0897
Market cap$6.22M$5.07M
1-day change-2.12%-12.91%
YTD return+153.05%-93.40%
1-year return+97.62%-93.64%
5-year return-59.47%—
Forward P/E—0.64
EPS (TTM)$-5.60$-0.55
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$401.95M$22.54M
Revenue growth (YoY)-12.34%-39.15%
Net income (latest FY)$-49.19M$-27.28M
Gross margin27.73%83.79%
Operating margin-6.58%-113.73%
Net margin-12.24%-121.04%
52-week high$45.20$3.70
52-week low$2.05$0.073
Distance from 52-week high-95.41%-97.58%
Analyst consensusnonenone
Avg. price target upside—+4359.31%
Average volume201.35K16.31M
Shares outstanding3.00M56.52M
Employees809146
SectorHealth CareHealth Care
IndustryMedical/Dental InstrumentsMedical/Dental Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ARAY has outperformed BDMD by 191.3 percentage points over the past year.
  • Accuray is more profitable, keeping -12.2 cents of every revenue dollar as net income versus -121.0 cents for Baird Medical Investment.
  • Accuray grew revenue faster in its latest fiscal year (-12.34% vs -39.15%).

About Accuray

ARAY stock →

Accuray Incorporated engages in the design, development, and sale of radiosurgery and radiation therapy systems for the treatment of tumors throughout the body in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.

Health Care · Medical/Dental Instruments · 809 employees

About Baird Medical Investment

BDMD stock →

Baird Medical Investment Holdings Limited, together with its subsidiaries, engages in research, development, manufacturing, and sales of microwave ablation and other medical devices in the People's Republic of China. The company offers microwave ablation apparatus and needles; and long and fine microwave ablation needles for the treatment of benign and malignant tumors, including thyroid nodules, liver cancer, lung cancer, and breast lumps, and uterine fibroids, as well as soft tissue ablation.

Health Care · Medical/Dental Instruments · 146 employees

ARAY vs BDMD FAQ

Which is bigger, Accuray or Baird Medical Investment?

Accuray (ARAY) is larger, with a market capitalization of $6.22M compared with $5.07M for Baird Medical Investment (BDMD).

Which stock has performed better over the past year, ARAY or BDMD?

ARAY returned +97.62% over the past 12 months, compared with -93.64% for BDMD (price return, excluding dividends). Past performance does not predict future results.

Are Accuray and Baird Medical Investment in the same industry?

Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.

More comparisons